Recently, greater clinical benefit has been seen with the use of albumin-bound sirolimus (nab-sirolimus, FYARRO) in the treatment of PEComa: 39% of patients had PRs, with median duration of response of 40 months, and there was a 7% complete response rate (including a patient with surgical resection of residual disease) (44). The gene discussed is ALB; the disease is neoplasm with perivascular epithelioid cell differentiation.